Journal
CELLS
Volume 9, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/cells9040883
Keywords
omomyc; Myc; cancer; Myc inhibition; mouse models; peptides; anticancer drugs; new therapeutics
Categories
Funding
- European Commission (SME Instrument) [872212]
- Instituto de Salud Carlos III (FIS) [PI16-01224]
- European Research Council (CoG) [617473]
- European Research Council (ERC) [617473] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. The recently described therapeutic effect of purified Omomyc mini-protein-following the surprising discovery of its cell-penetrating capacity-constitutes a paradigm shift. Now, much more than a proof of concept, the most characterized Myc inhibitor to date is advancing in its drug development pipeline, pushing Myc inhibition into the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available